Fig. 6.

Effect of combined AZD8931 and trametinib treatment on phospho-ERK and phospho-EGFR levels in UMSCC25 cells. UMSCC25 cells were treated with AZD8931 (0–100 nM) in the presence or absence of 3 nM trametinib, and cell extracts were prepared after 1, 6, 24, and 72 hours of treatment. The extracts were submitted to SDS-PAGE and immunoblotted for phospho-EGFR (mixture of anti-Y1068 and Y1148) as well as phospho-ERK and phospho-Ser473-AKT. The filters were stripped and reprobed for total EGFR, ERK, AKT, and Na/K-ATPase α-subunit levels as loading controls. The relative levels of p-EGFR/EGFR and p-ERK/ERK following densitometry of the autoradiographic films are shown, and the data are representative of another independent experiment.